News from cardio3 biosciences A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 02, 2015, 11:48 ET Cardio3 BioSciences marks first important milestone in regulatory path toward C-Cure® market registration with Paediatric Investigation Plan waiver from EMA

 Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of specialized cell therapies, today...


Feb 24, 2014, 08:24 ET Cardio3 BioSciences Strengthens IP Portfolio with New US Patent

Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...


Jan 09, 2014, 09:00 ET Cardio3 BioSciences Receives IND Clearance from the FDA for its CHART-2 Phase III Heart Failure Clinical Trial

Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...


Jan 08, 2014, 11:09 ET Cardio3 BioSciences, a European biopharmaceutical company, now covered by Edison Investment Research

 Edison's comprehensive report on Cardio3 BioSciences, Healing failing hearts, analyses its C-Cure heart regenerative product, which uses a mix...


Dec 30, 2013, 06:30 ET Cardio3 BioSciences Announces Participation at the 32nd Annual JP Morgan Healthcare Conference in San Francisco

Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...


Dec 16, 2013, 13:27 ET Cardio3 BioSciences Raises € 4.0 Million in Non-dilutive Funding from the Walloon Region

The biotechnology company, Cardio3 BioSciences SA ('Cardio3' or 'the Company'), a leader in the discovery and development of regenerative,...


Dec 11, 2013, 12:00 ET Cardio3 BioSciences C-Cath® Article Published in Circulation Cardiovascular Interventions

  Study Demonstrates Enhanced Endomyocardial Therapeutics Retention through an Optimized Delivery System Cardio3 BioSciences (C3BS) (NYSE...


Dec 03, 2013, 11:35 ET Cardio3 BioSciences Partner and Exploitation Manager of a Eur 6.8 Million FP7 Research Grant for AMCARE Program

Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...